Keywords: ASCO, Bayer, Nexavar, Sorafenib, Melanoima, Bristol-Myers Squibb, Ipipimumab

Combination treatment, including Bayer’s sorafenib, regimen not effective against advanced melanoma; B-MS’ ipilimumab good in MM

Article | 07 June 2010

Print This

The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in